Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Glioma D005910 112 associated lipids
Weight Gain D015430 101 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Brain Ischemia D002545 89 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Seizures D012640 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Atherosclerosis D050197 85 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Alzheimer Disease D000544 76 associated lipids
Stomach Ulcer D013276 75 associated lipids
Leukemia D007938 74 associated lipids
Coronary Disease D003327 70 associated lipids
Colitis D003092 69 associated lipids
Melanoma D008545 69 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Neuroblastoma D009447 66 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Reperfusion Injury D015427 65 associated lipids
Pain D010146 64 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Weight Loss D015431 56 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Nerve Degeneration D009410 53 associated lipids
Parkinson Disease D010300 53 associated lipids
Asthma D001249 52 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Osteosarcoma D012516 50 associated lipids
Thrombosis D013927 49 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Psoriasis D011565 47 associated lipids
Metabolism, Inborn Errors D008661 46 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Hyperalgesia D006930 42 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Leukemia, Experimental D007942 42 associated lipids
Hypotension D007022 41 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Arthritis D001168 41 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Zellweger Syndrome D015211 39 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Peritonitis D010538 38 associated lipids
Lung Diseases D008171 37 associated lipids
Nervous System Diseases D009422 37 associated lipids
Liver Cirrhosis, Experimental D008106 36 associated lipids
Fever D005334 35 associated lipids
Glomerulonephritis D005921 35 associated lipids
Anaphylaxis D000707 35 associated lipids
Epilepsy D004827 35 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Anemia, Sickle Cell D000755 34 associated lipids
Burns D002056 34 associated lipids
Acute Lung Injury D055371 33 associated lipids
Uremia D014511 33 associated lipids
Memory Disorders D008569 33 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Hypertension, Pulmonary D006976 32 associated lipids
Stroke D020521 32 associated lipids
Cardiomegaly D006332 31 associated lipids
Proteinuria D011507 30 associated lipids
Endometrial Neoplasms D016889 30 associated lipids
Vitamin E Deficiency D014811 29 associated lipids
Neuralgia D009437 28 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Gastritis D005756 27 associated lipids
Mammary Neoplasms, Animal D015674 27 associated lipids
Endotoxemia D019446 27 associated lipids
Angina Pectoris D000787 27 associated lipids
Hyperinsulinism D006946 27 associated lipids
Brain Diseases D001927 27 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Nasal Polyps D009298 26 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Ascites D001201 25 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Pulmonary Fibrosis D011658 24 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Namm DH et al. Species specificity of the platelet responses to 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine. 1982 Thromb. Res. pmid:7071810
Keraly CL and Benveniste J Specific desensitization of rabbit platelets by platelet-activating factor (PAF-acether) and derivatives. 1982 Br. J. Haematol. pmid:7082588
Wykle RL et al. Platelet activating factor (1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine). Activity of analogs lacking oxygen at the 2-position. 1982 FEBS Lett. pmid:7084476
Sánchez-Crespo M et al. Vascular actions of synthetic PAF-acether (a synthetic platelet-activating factor) in the rat: evidence for a platelet independent mechanism. 1982 Immunopharmacology pmid:7085259
Bach MK Mediators of anaphylaxis and inflammation. 1982 Annu. Rev. Microbiol. pmid:6128957
Mueller HW et al. Ether lipid content and fatty acid distribution in rabbit polymorphonuclear neutrophil phospholipids. 1982 Lipids pmid:7087685
Haslam RJ and Vanderwel M Inhibition of platelet adenylate cyclase by 1-O-alkyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine (platelet-activating factor). 1982 J. Biol. Chem. pmid:6177688
Page CP et al. Platelet activation in asthma. 1982 N. Engl. J. Med. pmid:7088080
Vargaftig BB et al. Degranulation of rabbit platelets with PAF-acether: a new procedure for unravelling the mode of action of platelet-activating substances. 1982 Thromb. Haemost. pmid:7135345
Sancho J et al. The effect of the injection of a synthetic platelet-activating factor (PAF-acether) on the fate of IgG aggregates in mice. 1982 Immunology pmid:7141463
Chignard M et al. Inhibition by sulphinpyrazone of the platelet-dependent bronchoconstriction due to platelet-activating factor (PAF-acether) in the guinea pig. 1982 Eur. J. Pharmacol. pmid:6804248
Lüscher EF The role of blood cells and of the vessel wall in the induction of intravascular coagulation. 1982 Klin. Wochenschr. pmid:6750223
Czarneztki BM Effect of platelet activating factor on leukocytes. II. Enhancement of eosinophil chemotactic factor and beta-glucuronidase release. 1982 Chem. Phys. Lipids pmid:6814773
Basran GS et al. Cromoglycate (DSCG) inhibits responses to platelet-activating factor (PAF-acether) in man: an alternative mode of action for DSCG in asthma? 1982 Eur. J. Pharmacol. pmid:6819153
Shaw JO and Lyons RM Requirements for different Ca2+ pools in the activation of rabbit platelets. I. release reaction and protein phosphorylation. 1982 Biochim. Biophys. Acta pmid:6800409
Aderka D et al. Morphological platelet anomalies in thrombotic thrombocytopenic purpura. 1982 Acta Haematol. pmid:6801893
Lapetina EG Platelet-activating factor stimulates the phosphatidylinositol cycle. Appearance of phosphatidic acid is associated with the release of serotonin in horse platelets. 1982 J. Biol. Chem. pmid:7045103
Hartung HP et al. Stimulation of the oxidative burst in macrophages with platelet activating factor (PAF-acether). 1982 Agents Actions Suppl. pmid:6960648
Wasserman SI Mediators of immediate hypersensitivity. 1983 J. Allergy Clin. Immunol. pmid:6193157
Alam I et al. Human and rabbit platelets form platelet-activating factor in response to calcium ionophore. 1983 Thromb. Res. pmid:6407140
Ostermann G et al. Studies on the stimulation of human blood platelets by semi-synthetic platelet-activating factor. 1983 Thromb. Res. pmid:6408754
Hopkins NK et al. Evidence for mediation of acetyl glyceryl ether phosphorylcholine stimulation of adenosine 3',5'-(cyclic)monophosphate levels in human polymorphonuclear leukocytes by leukotriene B4. 1983 Biochim. Biophys. Acta pmid:6313071
Czarnetzki B Increased monocyte chemotaxis towards leukotriene B4 and platelet activating factor in patients with inflammatory dermatoses. 1983 Clin. Exp. Immunol. pmid:6317241
Stimler NP and O'Flaherty JT Spasmogenic properties of platelet-activating factor: evidence for a direct mechanism in the contractile response of pulmonary tissues. 1983 Am. J. Pathol. pmid:6624879
Hartung HP Acetyl glyceryl ether phosphorylcholine (platelet-activating factor) mediates heightened metabolic activity in macrophages. Studies on PGE, TXB2 and O2- production, spreading, and the influence of calmodulin-inhibitor W-7. 1983 FEBS Lett. pmid:6309563
Swendsen CL et al. 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine: a novel source of arachidonic acid in neutrophils stimulated by the calcium ionophore A23187. 1983 Biochem. Biophys. Res. Commun. pmid:6407484
Ogihara T et al. [Renomedullary hypotensive lipids and prostaglandins]. 1983 Horumon To Rinsho pmid:6368051
Billah MM and Johnston JM Identification of phospholipid platelet-activating factor (1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in human amniotic fluid and urine. 1983 Biochem. Biophys. Res. Commun. pmid:6407483
Vargaftig BB Phospholipids, particularly platelet-activating factor (PAF-acether), in experimental bronchoconstriction. 1983 Agents Actions Suppl. pmid:6575594
Page CP et al. PAF-acether: a putative mediator of asthma and inflammation. 1983 Agents Actions Suppl. pmid:6575595
Chilton FH et al. Selective acylation of lyso platelet activating factor by arachidonate in human neutrophils. 1983 J. Biol. Chem. pmid:6408071
Lecrubier C et al. Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin. 1983 Agents Actions pmid:6858789
Hartung HP et al. Platelet activating factor (PAF) induces the oxidative burst in macrophages. 1983 Int. J. Immunopharmacol. pmid:6874164
Gonzalez-Crussi F and Hsueh W Experimental model of ischemic bowel necrosis. The role of platelet-activating factor and endotoxin. 1983 Am. J. Pathol. pmid:6859226
1st International Symposium on Platelet-Activating Factor (PAF-ACETHER, AGEPC) and structurally related ether-lipids. Paris (France) June 26-29, 1983. Abstracts. 1983 J Pharmacol pmid:6876807
Camussi G et al. Acute lung inflammation induced in the rabbit by local instillation of 1-0-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine or of native platelet-activating factor. 1983 Am. J. Pathol. pmid:6859232
Sánchez-Crespo M et al. Presence in normal human urine of a hypotensive and platelet-activating phospholipid. 1983 Am. J. Physiol. pmid:6859262
Lumb RH et al. Spontaneous and protein-catalyzed transfer of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) between phospholipid bilayers. 1983 Biochim. Biophys. Acta pmid:6860678
Suquet CM and Leid RW Aggregation of equine platelets by PAF (platelet-activating factor). 1983 Inflammation pmid:6862593
Blank ML and Snyder F Improved high-performance liquid chromatographic method for isolation of platelet-activating factor from other phospholipids. 1983 J. Chromatogr. pmid:6863454
Simrock R et al. [Reversible inhibition of thrombocyte stimulation by acetylsalicylic acid and its role in antithrombotic therapy]. 1983 Klin. Wochenschr. pmid:6865264
Pieroni G and Hanahan DJ Metabolic behavior of acetyl glyceryl ether phosphorylcholine on interaction with rabbit platelets. 1983 Arch. Biochem. Biophys. pmid:6870274
Camussi G et al. Effect of prostacyclin (PGI2) on immune-complex-induced neutropenia. 1983 Immunology pmid:6339375
Billah MM and Lapetina EG Platelet-activating factor stimulates metabolism of phosphoinositides in horse platelets: possible relationship to Ca2+ mobilization during stimulation. 1983 Proc. Natl. Acad. Sci. U.S.A. pmid:6341992
Lapetina EG and Siegel FL Shape change induced in human platelets by platelet-activating factor. Correlation with the formation of phosphatidic acid and phosphorylation of a 40,000-dalton protein. 1983 J. Biol. Chem. pmid:6345519
Camussi G et al. Inhibitory effect of prostacyclin (PGI2) on neutropenia induced by intravenous injection of platelet-activating-factor (PAF) in the rabbit. 1983 Prostaglandins pmid:6346397
Iñarrea P et al. Platelet-activating factor: an effector substance of the vasopermeability changes induced by the infusion of immune aggregates in the mouse. 1983 Immunopharmacology pmid:6347969
Satouchi K [Platelet activating factor (PAF)--a new chemical mediator of inflammation]. 1983 Seikagaku pmid:6350499
McGowan EB and Detwiler TC Characterization of the thrombin-induced desensitization of platelet activation by thrombin. 1983 Thromb. Res. pmid:6356458
Weksler BB Platelets and the inflammatory response. 1983 Clin. Lab. Med. pmid:6360503